Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › FDA Issues Warning Letter to Becton Dickinson Over Facility Violations

FDA Issues Warning Letter to Becton Dickinson Over Facility Violations

Jan 11, 2018
|
staff reporter

This article has been updated to include a response from Becton Dickinson.

NEW YORK (360DX) – The US Food and Drug Administration today issued a warning letter to Becton Dickinson, outlining a number of violations of federal law related to the company's Vacutainer blood collection tubes, including changes it made to the tubes and its failure to investigate complaints about their performance.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Oct
09
Featured Webinar

Navigating the FDA's EUA Process for Diagnostics in the Present and Future: A Stakeholder Panel Discussion

Sponsored by
PerkinElmer

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.

What's Popular?

In Regulatory News & FDA Approvals

  1. DiaSorin Receives CE Mark to Use Saliva Samples With COVID-19 Test

  2. Roche Gets FDA Emergency Use Authorization for Rapid Coronavirus, Flu Test

  3. FDA Proposes Reclassification of Cytomegalovirus Quantitative Tests

  4. Cytek Biosciences Gets CE Mark for Flow Cytometer

  5. Eurobio Gets CE Mark for Multiplexed SARS-CoV-2, Influenza A/B, RSV Test

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.